Form 4: Humacyte Director Charles Bruce Green Granted 80,000 Stock Options

Humacyte, Inc. Director Charles Bruce Green was granted 80,000 stock options with an exercise price of $2.41, vesting over four years.

Summary

• Charles Bruce Green, a Director of Humacyte, Inc. [HUMA], was granted 80,000 stock options.
• The options have an exercise price of $2.41 per share.
• The transaction date for the option grant was June 12, 2025.
• The first 25% of the options become exercisable on June 12, 2026.
• Following the initial vesting, 1/48th of the option will vest on the 12th of each month through June 12, 2029.
• The options expire on June 12, 2035.
• This transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal as it aligns management's interests with shareholders, incentivizing long-term performance. It's a standard compensation practice, so not exceptionally positive, but certainly not negative.

Positives

• A company director, Charles Bruce Green, was granted a significant number of stock options (80,000), which aligns his interests with shareholder value by incentivizing long-term stock price appreciation.
• The grant was made under a Rule 10b5-1(c) plan, indicating a pre-arranged transaction and potentially a long-term commitment to the company's performance.

Risks

• The value of the stock options is dependent on Humacyte, Inc.'s stock price exceeding the exercise price of $2.41.
• Future stock price volatility could impact the realized value of these options.

Future Outlook

This document primarily reports a past transaction (option grant) and its future vesting schedule. It does not provide a general future outlook for the company's performance or strategic direction.

Industry Context

This is an individual insider transaction, which is a common form of executive compensation in publicly traded companies, particularly in the biotech/healthcare industry where long-term incentives are crucial for retaining talent and aligning interests with company growth.

Comparison to Industry Standards

• The grant of 80,000 stock options to a director is a standard practice for executive compensation in publicly traded companies.
• The vesting schedule, with an initial cliff followed by monthly vesting over several years (June 12, 2026, to June 12, 2029), is a common structure designed to incentivize long-term commitment and performance.
• The exercise price of $2.41 is typical for options granted at or near the market price on the grant date, aligning the director's potential gains with future stock appreciation.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders by incentivizing long-term stock price appreciation, potentially leading to improved company performance.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• The stock options will begin vesting on June 12, 2026.
• Subsequent vesting will occur monthly until June 12, 2029.

Key Dates

Keywords

Humacyte, HUMA, Stock Options, Insider Trading, SEC Form 4, Director Compensation, Equity Grant, Rule 10b5-1